Stocks · News reference

HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $27

Aug 10, 2026, 11:58 AMBenzinga Newsdesk

HC Wainwright & Co. analyst Robert Burns maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $25 to $27.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Globenewswire IncAug 7, 2026, 8:30 PMNa
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals granted 125,400 non-qualified stock options and 20,550 restricted stock units to five new non-executive employees as inducement for employment. The grants were approved by the Compensation Committee and comply with Nasdaq Rule 5635(c)(4). The company continues development of its clinical-stage oncology candidates including rinzimetostat for prostate cancer and enozertinib for NSCLC.
Read original at globenewswire-inc
ORIC
BenzingaAug 3, 2026, 8:57 PMBenzinga Newsdesk
ORIC Pharmaceuticals Q2 EPS $(0.38) Misses $(0.36) Estimate
ORIC Pharmaceuticals (NASDAQ:ORIC) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.36) by 5.56 percent. This is a 19.15 percent increase over losses of $(0.47) per share
Read original at benzinga
ORIC
SEC EDGARAug 3, 2026, 8:10 PMSEC EDGAR
8-K filing — Oric Pharmaceuticals, Inc. (ORIC)
Filed: 2026-08-03 AccNo: 0001193125-26-330568 Size: 423 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar
ORIC